(Source: Karyopharm Therapeutics Inc) NEWTON, Mass., Nov. 5, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that 17 abstracts, including 5 oral presentations and 12 posters describing the activity of its oncology pipeline for the treatment of hematologic malignancies, have been selected for presentation at the 2015 American Society of Hematology (ASH) annual meeting taking place December 5-8, 2015 in Orlando, Florida. The abstracts, which represent both company and investigator-sponsored clinical and preclinical studies, describe data related to selinexor, Karyopharm's first-in-class, oral Selective Inhibitor of...
↧
